Aytu BioPharma (AYTU) director receives 10,000 restricted shares

Rhea-AI Filing Summary

Donofrio John Jr. reported acquisition or exercise transactions in this Form 4 filing.

Aytu BioPharma, Inc. director John Donofrio Jr. received a grant of 10,000 shares of restricted common stock on July 28, 2026. The award vests on July 28, 2027 and was priced at $0.00 per share, bringing his direct holdings to 23,762 shares.

Insider Trade Summary

Net Buyer: 10,000 shares

Net Buy 1 txn

Insider Donofrio John Jr.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	10,000	$0.00	$0.00

Holdings After Transaction: Common Stock — 23,762 shares (Direct)

Footnotes (1)

1. F1. Grant of restricted stock, which vest on July 28, 2027.

Key Figures

Restricted stock granted: 10,000 shares Shares owned after grant: 23,762 shares Grant price: $0.00 per share +1 more

4 metrics

Restricted stock granted 10,000 shares Grant of restricted common stock to director on July 28, 2026

Shares owned after grant 23,762 shares Direct common stock holdings following the reported award

Grant price $0.00 per share Reported transaction price for the restricted stock award

Vesting date July 28, 2027 Date on which the granted restricted stock is scheduled to vest

Key Terms

restricted stock, vest, Grant, award, or other acquisition

3 terms

restricted stock financial

"Grant of <b>restricted stock</b>, which vest on July 28, 2027."

Shares granted to an individual that carry limits on transfer or sale until certain conditions are met, such as staying with the company for a set time or hitting performance targets. Think of them as a locked gift that gradually opens; for investors they matter because they affect how many shares may enter the market later, signal management incentives and potential dilution, and reveal confidence in future company performance.

vest financial

"Grant of restricted stock, which <b>vest</b> on July 28, 2027."

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

Grant, award, or other acquisition regulatory

"Transaction code A described as "<b>Grant, award, or other acquisition</b>"."

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/30/2026 - 04:31 PM Accepted by SEC EDGAR 07/30/2026 - 04:31 PM Learn about SEC filing dates

FAQ

What insider transaction did AYTU director John Donofrio Jr. report?

AYTU director John Donofrio Jr. reported a grant of 10,000 shares of restricted common stock on July 28, 2026. The award was priced at $0.00 per share and increased his direct ownership to 23,762 shares of Aytu BioPharma common stock.

When do the newly granted AYTU restricted shares vest?

The 10,000 shares of restricted Aytu BioPharma (AYTU) stock granted to director John Donofrio Jr. vest on July 28, 2027. Until that vesting date, the shares are subject to the restrictions described as a restricted stock award.

How many AYTU shares does John Donofrio Jr. own after this grant?

Following the grant, John Donofrio Jr. directly owns 23,762 shares of Aytu BioPharma (AYTU) common stock. This figure includes the 10,000 restricted shares awarded on July 28, 2026, as reported in the insider transaction data.

Was the AYTU restricted stock grant to John Donofrio Jr. a market purchase?

No, the transaction is coded as a grant, award, or other acquisition of common stock, not a market purchase. The 10,000 AYTU shares were awarded at $0.00 per share as restricted stock, vesting on July 28, 2027.

Is the AYTU Form 4 transaction under a Rule 10b5-1 trading plan?

The Form 4 for Aytu BioPharma (AYTU) indicates the Rule 10b5-1 checkbox is not marked as affirmative. The reported grant of 10,000 restricted shares to director John Donofrio Jr. is therefore not flagged as executed under a Rule 10b5-1 trading plan.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Donofrio John Jr.

(Last) (First) (Middle)

C/O AYTU BIOPHARMA, INC.

7900 EAST UNION AVENUE, SUITE 920

(Street)

DENVER COLORADO 80237

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AYTU BIOPHARMA, INC [ AYTU ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/28/2026		A		10,000(1)	A	$0	23,762	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Grant of restricted stock, which vest on July 28, 2027.

	/s/ Ryan J. Selhorn as attorney-in-fact for John A. Donofrio, Jr.	07/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)